Trial
NCT02447887
Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Fox Chase Cancer Center
Collaborators
—
Condition
Metastatic Renal Cell Carcinoma
Intervention
Ixazomib
Why stopped
IRB study closure facilitated by Investigator
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-09-26